Barbara Boughton | Authors

December 05, 2010

Patients with early-stage Hodgkin’s lymphoma and a favorable prognosis can be treated with less intensive chemotherapy and radiotherapy regimens without affecting outcomes. This is the first study to show that less intensive therapy can be used without sacrificing benefits, according to lead author Andreas Engert, MD, and colleagues.

November 23, 2010

The saying that “knowledge is power” holds especially true when it comes to a lymphoma diagnosis, and there are best practices for clinicians who want to fully educate their patients. Presentations at ASH 2010 offer data and advice on how to approach&#151and improve&#151education efforts among clinicians and patients.

October 20, 2010

Canadian researchers also find that patients are not having recommended cancer screening studies done on a regular basis.

September 02, 2010

Combined with first-line chemotherapy, intravenous delivery therapy also confers a survival benefit over oral bisphosphonates. Gareth J. Morgan, MD, PhD, lead investigator of the Medical Research Council Myeloma IX study, will share additional trial results at ASH 2010.

August 10, 2010

Eighteen-month follow up supports lower-dose nilotinib as the new standard of care for newly diagnosed chronic myeloid leukemia. The ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+CML Patients) enrolled 846 patients at 217 sites in 35 countries. Timothy P. Hughes, MD, MBBS, will present an update to the ENESTnd trial at ASH 2010.

July 13, 2010

Physicians must engage and educate patients about significant risk for cardiovascular disease.

July 13, 2010

HIV’s disruption of immune system function may cause the immune system cells themselves to become cancerous, NCI researchers have concluded. If so, this might explain why patients with AIDS are 100 times more likely to be diagnosed with non-Hodgkin’s lymphoma than the general population.

April 14, 2010

Mismanaged therapy at one institution has dealt a blow to the field, but practitioners explain why the technique remains worthwhile.

March 18, 2010

Testing for EGFR and ALK mutations reveals tumor behavior and helps tailor treatment.

November 24, 2009

Surgical intervention for mesothelioma has become widely accepted, but controversy persists: Should surgery be the standard of care or should it be offered only to select patients? According to scientific literature, surgery decreases morbidity and mortality while also improving outcomes compared with adjunctive therapy alone.